PL373414A1 - Pochodne 8-metoksy-(1,2,4)-triazolo(1,5-a)pirydyny i ich zastosowanie jako ligandów receptora adenozynowego - Google Patents

Pochodne 8-metoksy-(1,2,4)-triazolo(1,5-a)pirydyny i ich zastosowanie jako ligandów receptora adenozynowego

Info

Publication number
PL373414A1
PL373414A1 PL02373414A PL37341402A PL373414A1 PL 373414 A1 PL373414 A1 PL 373414A1 PL 02373414 A PL02373414 A PL 02373414A PL 37341402 A PL37341402 A PL 37341402A PL 373414 A1 PL373414 A1 PL 373414A1
Authority
PL
Poland
Prior art keywords
triazolo
methoxy
adenosine receptor
receptor ligands
pyridine derivatives
Prior art date
Application number
PL02373414A
Other languages
English (en)
Inventor
Matthias Heinrich Nettekoven
Bernd Puellmann
Original Assignee
F.Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F.Hoffmann-La Roche Ag filed Critical F.Hoffmann-La Roche Ag
Publication of PL373414A1 publication Critical patent/PL373414A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL02373414A 2001-07-20 2002-07-10 Pochodne 8-metoksy-(1,2,4)-triazolo(1,5-a)pirydyny i ich zastosowanie jako ligandów receptora adenozynowego PL373414A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01117539 2001-07-20

Publications (1)

Publication Number Publication Date
PL373414A1 true PL373414A1 (pl) 2005-08-22

Family

ID=8178085

Family Applications (1)

Application Number Title Priority Date Filing Date
PL02373414A PL373414A1 (pl) 2001-07-20 2002-07-10 Pochodne 8-metoksy-(1,2,4)-triazolo(1,5-a)pirydyny i ich zastosowanie jako ligandów receptora adenozynowego

Country Status (13)

Country Link
US (1) US6514989B1 (pl)
EP (1) EP1412352A1 (pl)
JP (1) JP4105089B2 (pl)
KR (1) KR100592939B1 (pl)
CN (1) CN1264840C (pl)
AR (1) AR034870A1 (pl)
AU (1) AU2002325316B2 (pl)
BR (1) BR0211206A (pl)
CA (1) CA2453919A1 (pl)
MX (1) MXPA04000532A (pl)
PL (1) PL373414A1 (pl)
RU (1) RU2297416C2 (pl)
WO (1) WO2003010167A1 (pl)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6693116B2 (en) * 2001-10-08 2004-02-17 Hoffmann-La Roche Inc. Adenosine receptor ligands
AU2002358597C1 (en) * 2001-12-12 2008-09-18 F. Hoffmann-La Roche Ag Benzothiophenes as adenosine receptor modulators
MY139563A (en) * 2002-09-04 2009-10-30 Bristol Myers Squibb Co Heterocyclic aromatic compounds useful as growth hormone secretagogues
CN1830978B (zh) * 2005-03-07 2010-06-16 中国人民解放军军事医学科学院毒物药物研究所 吡唑并[4,3-c]喹啉-3-酮化合物、其制备方法及其应用
CA2655310A1 (en) * 2006-06-22 2008-05-29 Cv Therapeutics, Inc. Use of a2a adenosine receptor agonists in the treatment of ischemia
BRPI0716239A2 (pt) * 2006-08-30 2013-08-13 Cellzome Ltd derivados de triazol como inibidores de cinase
EP1894931A1 (en) * 2006-08-30 2008-03-05 Cellzome Ag Triazole derivatives as kinase inhibitors
HUP0700395A2 (en) 2007-06-07 2009-03-02 Sanofi Aventis Substituted [1,2,4] triazolo [1,5-a] quinolines, process for their preparation, pharmaceutical compositions thereof, and intermediates
GB0719803D0 (en) * 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
AU2008328882A1 (en) * 2007-11-27 2009-06-04 Cellzome Limited Amino triazoles as PI3K inhibitors
WO2009155565A1 (en) * 2008-06-20 2009-12-23 Genentech, Inc. Triazolopyridine jak inhibitor compounds and methods
CN102131389A (zh) * 2008-06-20 2011-07-20 健泰科生物技术公司 三唑并吡啶jak抑制剂化合物和方法
WO2010010188A1 (en) * 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases.
JO3041B1 (ar) * 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
TWI453207B (zh) * 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶，其組合物及使用其之治療方法
HRP20160488T1 (hr) * 2008-12-19 2016-06-17 Leo Pharma A/S Triazolopiridini kao inhibitori fosfodiesteraze za liječenje kožnih bolesti
EP2438066A2 (en) 2009-06-05 2012-04-11 Cephalon, Inc. PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a]PYRIDINE DERIVATIVES
TWI462920B (zh) * 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
JO3030B1 (ar) * 2009-06-26 2016-09-05 Galapagos Nv مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
EP3594213A1 (en) * 2009-07-17 2020-01-15 Japan Tobacco Inc. Triazolopyridine compounds and action thereof as prolyl hydroxylase inhibitors and erythropoietin production inducers
EP2343297A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
US8080568B1 (en) * 2010-06-29 2011-12-20 Ewha University - Industry Collaboration Foundation 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors
MX2014005285A (es) * 2011-11-03 2014-05-30 Hoffmann La Roche Compuestos biciclicos de piperazina.
CA2858123A1 (en) * 2011-12-21 2013-06-27 Leo Pharma A/S [1,2,4]triazolopyridines and their use as phosphodiesterase inhibitors
WO2013135612A1 (en) 2012-03-14 2013-09-19 Bayer Intellectual Property Gmbh Substituted imidazopyridazines
AP2015008898A0 (en) 2013-06-11 2015-12-31 Bayer Pharma AG Prodrug derivatives of substituted triazolopyridines
RU2563254C2 (ru) * 2013-07-08 2015-09-20 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Способ получения производных 7-(гетеро)арил-4,5,6,7-тетрагидро[1,2,3]триазоло[1,5-a]пиридина
GB201402071D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
GB201402070D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Pharmaceutical compositions for the treatment of inflammatory disorders
GB201808575D0 (en) 2018-05-24 2018-07-11 Galapagos Nv Methods for the treatment of psoriatic arthrits
AR117291A1 (es) 2018-12-14 2021-07-28 Syngenta Crop Protection Ag Compuestos heterocíclicos de cianamida con actividad pesticida
CN113646313B (zh) * 2019-03-28 2023-05-30 基石药业（苏州）有限公司 一种a2a受体拮抗剂的盐型、晶型及其制备方法
WO2021023207A1 (zh) * 2019-08-06 2021-02-11 江苏柯菲平医药股份有限公司 Jak激酶抑制剂及其用途
CN114907182A (zh) * 2019-09-09 2022-08-16 武汉诺安药业有限公司 一种4-碘代叔戊基苯的清洁制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9226735D0 (en) 1992-12-22 1993-02-17 Ici Plc Azole derivatives
HU208693B (en) * 1991-02-22 1993-12-28 Egyt Gyogyszervegyeszeti Gyar Process for producing 1,2,4-triazolo (1,5-a) pyrimidinis derivatives and their carbicycli-tetrahydro-thiofurane-tetrahydrothiopyrane-, or tetrahydropyridine- condensated derivatives or medical preparatives containing them
IT1258790B (it) * 1992-01-17 1996-02-29 Angelini Francesco Ist Ricerca Alchil derivati del trazodone
US5571775A (en) 1994-07-11 1996-11-05 Dowelanco N-aryl[1,2,4]triazolo[1,5-a]pyridine-2-sulfonamide herbicides
DE4432860A1 (de) * 1994-09-15 1996-03-21 Merck Patent Gmbh Imidazopyridine
US6355653B1 (en) 1999-09-06 2002-03-12 Hoffmann-La Roche Inc. Amino-triazolopyridine derivatives

Also Published As

Publication number Publication date
CA2453919A1 (en) 2003-02-06
CN1264840C (zh) 2006-07-19
BR0211206A (pt) 2004-07-13
WO2003010167A1 (en) 2003-02-06
AU2002325316B2 (en) 2007-11-01
MXPA04000532A (es) 2004-05-04
EP1412352A1 (en) 2004-04-28
KR100592939B1 (ko) 2006-06-26
RU2004105260A (ru) 2005-07-10
AR034870A1 (es) 2004-03-24
AU2002325316B8 (en) 2003-02-17
CN1541216A (zh) 2004-10-27
RU2297416C2 (ru) 2007-04-20
KR20040023667A (ko) 2004-03-18
JP2005511492A (ja) 2005-04-28
JP4105089B2 (ja) 2008-06-18
US6514989B1 (en) 2003-02-04

Similar Documents

Publication Publication Date Title
PL373414A1 (pl) Pochodne 8-metoksy-(1,2,4)-triazolo(1,5-a)pirydyny i ich zastosowanie jako ligandów receptora adenozynowego
BG103417A (en) Condensed pyrimidine bicyclic derivatives
MY132106A (en) New pyridazin-3(2h)-one derivatives
MXPA05012466A (es) Derivados de quinolina como inhibidores de fosfodiesterasa.
NZ522326A (en) Adenosine A2A receptor antagonists
MY140398A (en) 4-AMINO-6-PHENYL-PYRROLO[2,3-d]PYRIMIDINE DERIVATIVES
MY138352A (en) Benzothiazole derivatives
IL158667A0 (en) Imidazo [1,2-a] pyridine derivatives for the prophylaxis and treatment of herpes viral infections
AU2002305143A1 (en) Pyrazolo'1,5-a!pyridine derivatives
MXPA03005464A (es) Agentes antivirales.
MXPA04000886A (es) Derivados de triazolil-imidazopiridina y triazolilpurinas empledos como ligandos del receptor de adenosina a2a y su uso como medicamentos.
MXPA05007562A (es) Compuestos de pirazolotriazina y usos de los mismos.
WO2002036562A3 (en) 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
MY140872A (en) 5,7-diaminopyrazolo[4,3-d]pyrimidines with pde-5 inhibitory activity, compositions containing such derivatives and the use of such derivatives in the treatment of hypertension and other disorders
TW200626592A (en) Heterocyclic derivatives and their use as therapeutic agents
MX2007003321A (es) Derivados heterociclicos y su uso como agentes terapeuticos.
WO2002051837A3 (en) Heterocyclindazole and azaindazole compounds as 5-hydroxytryptamine-6 ligands
TW200626139A (en) Heterocyclic derivatives and their use as therapeutic agents
WO2005011653A3 (en) Pyridazine derivatives and their use as therapeutic agents
TW200626154A (en) Heterocyclic derivatives and their use as therapeutic agents
AU2002218167A1 (en) N-phenyl-2-pyrimidine-amine derivatives
SG149067A1 (en) IMIDAZO[4,5-c]PYRIDINE COMPOUNDS AND METHODS OF ANTIVIRAL TREATMENT
IL155367A (en) 2,4,8-TRISUBSTITUTED-8H- PYRIDO[2,3-d]PYRIMIDIN-7-ONE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, PROCESSES FOR THE PREPARATION THEREOF AND USE THEREOF IN THE PREPARATION OF MEDICAMENTS FOR TREATING CSBP/P38 KINASE MEDIATED DISEASES
EP1633740A4 (en) CHEMICAL COMPOUNDS
MXPA04005156A (es) Antagonistas del receptor de adenosina a2a.

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)